Skip to main content
OpenTrials

Clinical trial condition

Purine-Pyrimidine Metabolism, Inborn Errors

Explore clinical trials studying Purine-Pyrimidine Metabolism, Inborn Errors. Study availability and eligibility vary by location and protocol.

266 public trials 34 recruiting studies
Refine in advanced search Browse all conditions

Purine-Pyrimidine Metabolism, Inborn Errors trial results

Completed

Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients

NCT04040816

Conditions
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Crystal Arthropathies, +12 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Anaheim Clinical Trials (ACT) Anaheim, California, United States
  • Miami Research Associates South Miami, Florida, United States
  • Advanced Clinical Research Meridian, Idaho, United States
View Trial Details
Completed

Placebo Controlled, Dose Escalation Study to Evaluate Safety, Pharmacokinetics & Efficacy of SAP-001 in Gout Patients

NCT03857165

Conditions
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Crystal Arthropathies, +13 more
Locations
  • Anaheim Clinical Trials, LLC Anaheim, California, United States
  • Avail - Accel Research Sites DeLand, Florida, United States
  • High Point Clinical Trials Center High Point, North Carolina, United States
View Trial Details
Completed

Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect

NCT02598596

Conditions
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Crystal Arthropathies, +9 more
Locations
  • University of Alabama at Birminingham Birmingham, Alabama, United States
  • Rheumatology Associates of North Alabama Huntsville, Alabama, United States
  • The Center for Rheumatology and Bone Research Wheaton, Maryland, United States
  • Clinical Pharmacology Study Group Worcester, Massachusetts, United States
View Trial Details
Completed

Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

NCT01431638

Conditions
Acute Gouty Arthritis, Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +12 more
Locations
  • Novartis Investigative Site Anniston, Alabama, United States
  • Novartis Investigative Site Gulf Shores, Alabama, United States
  • Novartis Investigative Site Mobile, Alabama, United States
  • Novartis Investigative Site Chandler, Arizona, United States
View all 68 locations
View Trial Details
Completed

β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)

NCT01470989

Conditions
Acute Gouty Arthritis Flares, Arthritis, Arthritis, Gouty, +11 more
Locations
  • Novartis Investigative Site Anniston, Alabama, United States
  • Novartis Investigative Site Mobile, Alabama, United States
  • Novartis Investigative Site Norwalk, California, United States
  • Novartis Investigative Site Pasadena, California, United States
View all 56 locations
View Trial Details
Completed

Long Term Study of Canakinumab (ACZ885) in Patients With Gout

NCT00927810

Conditions
Arthritis, Arthritis, Gouty, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +11 more
Locations
  • Novartis Investigative site Seattle, Washington, United States
  • Novartis Investigative site Capital Federal Buenos Aires, Argentina
  • Novartis Investigative site Jette, Belgium
  • Novartis Investigative site Barranquilla, Colombia
View all 45 locations
View Trial Details

Related conditions